Sarepta Therapeutics (NASDAQ: SRPT)
Sarepta Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Sarepta Therapeutics Company Info
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.
News & Analysis
Is This Stock a Buy After a Massive 20% Drop in 1 Day?
Top ETFs Tracking CRISPR Gene Editing
These exchange-traded funds track companies in this biotech space.
After a Big Win, Is Sarepta Therapeutics Stock a Buy?
One key issue remains unresolved, and it could be a significant one.
Has Sarepta Therapeutics Become a No-Brainer Stock Buy After This Recent FDA News?
The label expansion paves the way for much more revenue growth for Sarepta in the years ahead.
1 Soaring Growth Stock to Buy and Hold for 10 Years
Let's look beyond the biotech's performance this year.
1 Top Growth Stock to Buy and Hold for 10 Years
This company's lineup might look very different in a decade, but the end result will be the same for investors.
Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling?
The threat is still emerging, but it could be significant.
Sarepta Therapeutics Stock Has 73% Upside, According to 1 Wall Street Analyst
The upcoming regulatory decision on its latest drug could be big.
Valuation
Podcast Episodes
One Biotech Crashes, the Other Skyrockets -- Here's Why
Hit-or-miss data, delays, and contentious debate preceded the FDA's green-lighting of the first drug to target the cause of Duchenne muscular dystrophy. Meanwhile, a disappointing data readout stops one vaccine maker in its tracks.
Digging Into Disappointment: What Investors Need To Know About Sarepta and Gilead Sciences' "Bad News"
Discussing the details behind the FDA's negative vote on Sarepta's DMD drug and Gilead Sciences' sliding hepatitis C sales.
Earnings Transcripts
Sarepta Therapeutics (SRPT) Q4 2024 Earnings Call Transcript
SRPT earnings call for the period ending December 31, 2024.
Sarepta Therapeutics (SRPT) Q3 2024 Earnings Call Transcript
SRPT earnings call for the period ending September 30, 2024.
Sarepta Therapeutics (SRPT) Q2 2024 Earnings Call Transcript
SRPT earnings call for the period ending June 30, 2024.
Sarepta Therapeutics (SRPT) Q1 2024 Earnings Call Transcript
SRPT earnings call for the period ending March 31, 2024.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.